288 related articles for article (PubMed ID: 30426502)
21. Effectiveness of various human papillomavirus vaccination strategies: A community randomized trial in Finland.
Lehtinen M; Apter D; Eriksson T; Harjula K; Hokkanen M; Natunen K; Nieminen P; Paavonen J; Palmroth J; Petäjä T; Pukkala E; Vänskä S; Cheuvart B; Soila M; Bi D; Struyf F
Cancer Med; 2021 Nov; 10(21):7759-7771. PubMed ID: 34581025
[TBL] [Abstract][Full Text] [Related]
22. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing.
Lehtinen M; Apter D; Dubin G; Kosunen E; Isaksson R; Korpivaara EL; Kyhä-Osterlund L; Lunnas T; Luostarinen T; Niemi L; Palmroth J; Petäjä T; Rekonen S; Salmivesi S; Siitari-Mattila M; Svartsjö S; Tuomivaara L; Vilkki M; Pukkala E; Paavonen J
Int J STD AIDS; 2006 Aug; 17(8):517-21. PubMed ID: 16925896
[TBL] [Abstract][Full Text] [Related]
23. Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK.
Datta S; Pink J; Medley GF; Petrou S; Staniszewska S; Underwood M; Sonnenberg P; Keeling MJ
BMC Infect Dis; 2019 Jun; 19(1):552. PubMed ID: 31234784
[TBL] [Abstract][Full Text] [Related]
24. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
[TBL] [Abstract][Full Text] [Related]
25. Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors.
Woestenberg PJ; King AJ; van Benthem BHB; Donken R; Leussink S; van der Klis FRM; de Melker HE; van der Sande MAB; Hoebe CJPA; Bogaards JA;
J Infect Dis; 2018 Jan; 217(2):213-222. PubMed ID: 29140439
[TBL] [Abstract][Full Text] [Related]
26. Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014.
McClung NM; Gargano JW; Bennett NM; Niccolai LM; Abdullah N; Griffin MR; Park IU; Cleveland AA; Querec TD; Unger ER; Markowitz LE;
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):602-609. PubMed ID: 30792242
[TBL] [Abstract][Full Text] [Related]
27. Non-Vaccine-Type Human Papillomavirus Prevalence After Vaccine Introduction: No Evidence for Type Replacement but Evidence for Cross-Protection.
Saccucci M; Franco EL; Ding L; Bernstein DI; Brown D; Kahn JA
Sex Transm Dis; 2018 Apr; 45(4):260-265. PubMed ID: 29465705
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of human papillomavirus in teenage heterosexual males following the implementation of female and male school-based vaccination in Australia: 2014-2017.
Chow EPF; Tabrizi SN; Fairley CK; Wigan R; Machalek DA; Regan DG; Hocking JS; Garland SM; Cornall AM; Atchison S; Bradshaw CS; McNulty A; Owen L; Marshall L; Russell DB; Kaldor JM; Chen MY
Vaccine; 2019 Oct; 37(46):6907-6914. PubMed ID: 31562001
[TBL] [Abstract][Full Text] [Related]
29. Reduction in Vaccine HPV Type Infections in a Young Women Group (18-25 Years) Five Years after HPV Vaccine Introduction in Colombia.
Combita AL; Reyes V; Puerto D; Murillo R; Sánchez R; Nuñez M; Hernandez-Suarez GA; Wiesner C
Cancer Prev Res (Phila); 2022 Jan; 15(1):55-66. PubMed ID: 34610993
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women--implications for vaccination.
Moore RA; Ogilvie G; Fornika D; Moravan V; Brisson M; Amirabbasi-Beik M; Kollar A; Burgess T; Hsu R; Towers L; Lo J; Matisic J; Brooks-Wilson A
Cancer Causes Control; 2009 Oct; 20(8):1387-96. PubMed ID: 19475481
[TBL] [Abstract][Full Text] [Related]
31. Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial.
Lehtinen M; Apter D; Baussano I; Eriksson T; Natunen K; Paavonen J; Vänskä S; Bi D; David MP; Datta S; Struyf F; Jenkins D; Pukkala E; Garnett G; Dubin G
Vaccine; 2015 Mar; 33(10):1284-90. PubMed ID: 25593103
[TBL] [Abstract][Full Text] [Related]
32. Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States.
Chaturvedi AK; Graubard BI; Broutian T; Pickard RKL; Tong ZY; Xiao W; Kahle L; Gillison ML
J Clin Oncol; 2018 Jan; 36(3):262-267. PubMed ID: 29182497
[TBL] [Abstract][Full Text] [Related]
33. Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial.
Safaeian M; Sampson JN; Pan Y; Porras C; Kemp TJ; Herrero R; Quint W; van Doorn LJ; Schussler J; Lowy DR; Schiller J; Schiffman MT; Rodriguez AC; Gail MH; Hildesheim A; Gonzalez P; Pinto LA; Kreimer AR;
J Natl Cancer Inst; 2018 Feb; 110(2):205-12. PubMed ID: 28954299
[TBL] [Abstract][Full Text] [Related]
34. High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years After Vaccination in Young Dutch Women.
Donken R; King AJ; Bogaards JA; Woestenberg PJ; Meijer CJLM; de Melker HE
J Infect Dis; 2018 Apr; 217(10):1579-1589. PubMed ID: 29409034
[TBL] [Abstract][Full Text] [Related]
35. The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination.
Matthijsse SM; Hontelez JAC; Naber SK; van Rosmalen J; Rozemeijer K; Penning C; Bakker R; van Ballegooijen M; de Kok IMCM; de Vlas SJ
Vaccine; 2015 Oct; 33(41):5357-5364. PubMed ID: 26348405
[TBL] [Abstract][Full Text] [Related]
36. Impacts of human papillomavirus vaccination for different populations: A modeling study.
Baussano I; Lazzarato F; Ronco G; Franceschi S
Int J Cancer; 2018 Sep; 143(5):1086-1092. PubMed ID: 29603224
[TBL] [Abstract][Full Text] [Related]
37. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
Regan DG; Philp DJ; Hocking JS; Law MG
Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
[TBL] [Abstract][Full Text] [Related]
39. The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010-2016.
Mesher D; Panwar K; Thomas SL; Edmundson C; Choi YH; Beddows S; Soldan K
J Infect Dis; 2018 Aug; 218(6):911-921. PubMed ID: 29917082
[TBL] [Abstract][Full Text] [Related]
40. Public Health Benefits of Routine Human Papillomavirus Vaccination for Adults in the Netherlands: A Mathematical Modeling Study.
Matthijsse SM; Hontelez JA; Naber SK; Rozemeijer K; de Kok IM; Bakker R; van Ballegooijen M; van Rosmalen J; de Vlas SJ
J Infect Dis; 2016 Sep; 214(6):854-61. PubMed ID: 27330051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
